Tag:Drug Law

Citizen Petitions at the FDA: Professor Lietzan Interviewed by The Atlantic

March 20th, 2017

Professor Erika Lietzan was recently interviewed by a reporter for The Atlantic in connection with the use of “citizen petitions” at the U.S. Food & Drug Administration (FDA). A recent article in the New England Journal of

Read More

Professor Lietzan Quoted on “Right to Try” Legislation

March 17th, 2017

Professor Erika Lietzan was recently quoted in numerous papers around the country in connection with possible federal “right to try” legislation. Broadly speaking, the purpose of state “right to try” laws is to make it possible for

Read More

Professor Lietzan Presents “The Drug Innovation Paradox”

November 22nd, 2016

Professor Lietzan recently presented her latest paper, “The Drug Innovation Paradox,” at the Saint Louis University School of Law. This paper provides a historical and empirical study of the relationship between the drug premarket research and development

Read More

FDA’s Approval of Drug Fell Within Legal Authority: Professor Lietzan

October 7th, 2016

Professor Erika Lietzan was recently quoted by STAT regarding the Food & Drug Administration’s recent decision to grant accelerated approval to the first drug for Duchenne muscular dystrophy. The decision has attracted criticism, because approval was based

Read More

Professor Lietzan Publishes Article Critiquing Drug Legislation Pending in Congress

September 29th, 2016

Professor Lietzan has published an article in the Federalist Society Review critiquing drug legislation that is currently pending in the U.S. Senate. The “CREATES Act” would require innovative drug companies to sell their products to their competitors

Read More